Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study.
about
Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled studyExtended regimen combined oral contraception: A review of evolving concepts and acceptance by women and cliniciansAdherence to a flexible extended regimen for oral hormonal contraception provided in blister packaging compared with an adherence-supporting digital tablet dispenser: historical comparison of data from two clinical studiesAdherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter studyEfficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled studyAn update on new orally administered contraceptives for women.Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study.Continuous use of oral contraceptives: an overview of effects and side-effects.Evolution of extended use of the combined oral contraceptive pill.Extended regimens of combined hormonal contraception to reduce symptoms related to withdrawal bleeding and the hormone-free interval: a systematic review of randomised and observational studies.Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive.Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
P2860
Q28384507-4E71684D-7FB9-40AD-997B-3B062DCE60CEQ28392784-666B0A39-CD8B-4427-937C-2AB107BD9071Q30375900-CC2137EA-DE63-458B-8349-684E3992A294Q30420541-A30634FE-E17A-418A-B019-8ED1CF7F5E49Q33650417-579BF775-5B2D-4638-BA7B-8890AD597A96Q34499804-31A31083-BB3A-4084-A807-E4F960108C8CQ36785991-045FD6A9-BAAB-407F-AED1-C27FC30E2ED6Q38053497-F658BA0A-BDEC-4064-9F82-E6BCCF46009EQ38197591-016296EA-E25B-4B96-B48C-23DD97D0A820Q38223794-600BA4A5-F09C-4321-8E7E-E9D40785175BQ38245880-D745E6F0-DECA-4DF1-845C-D8FDBE614597Q48040189-C33A7948-B0F1-4BB3-8F5A-E95E2309D50F
P2860
Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Long-term tolerability of ethi ...... controlled, multicentre study.
@ast
Long-term tolerability of ethi ...... controlled, multicentre study.
@en
type
label
Long-term tolerability of ethi ...... controlled, multicentre study.
@ast
Long-term tolerability of ethi ...... controlled, multicentre study.
@en
prefLabel
Long-term tolerability of ethi ...... controlled, multicentre study.
@ast
Long-term tolerability of ethi ...... controlled, multicentre study.
@en
P2093
P2860
P1476
Long-term tolerability of ethi ...... controlled, multicentre study.
@en
P2093
Christine Klipping
Dietmar Trummer
Ingrid Duijkers
Joachim Marr
Jörg Elliesen
Michel P Fortier
P2860
P356
10.1136/JFPRHC-2011-100214
P577
2012-04-01T00:00:00Z